{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-025617","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.149292+00:00","generated_at":"2026-06-05T22:58:27.966342+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iovance prices $211M common stock offering at $9.15/share","bullets":["Issues 23,014,000 shares at $9.15; gross proceeds ~$211M, net ~$197.1M.","Net proceeds to support AMTAGVI commercial launch, NSCLC study IOV-LUN-202, melanoma trial TILVANCE-301.","Underwriters include Jefferies, Barclays, Goldman Sachs; closing expected Feb 22, 2024.","Executive officers and directors subject to 60-day lock-up on stock sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-025617","json":"https://secwatch.observer/filing/0001104659-24-025617.json","markdown":"https://secwatch.observer/filing/0001104659-24-025617.md","text":"https://secwatch.observer/filing/0001104659-24-025617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924025617/0001104659-24-025617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924025617/tm246746d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:58:27.966342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"96ffa800ccdc4f6b694449027f58dd84db2ca4f9","claim":"IOVANCE BIOTHERAPEUTICS, INC. entered into Underwriting Agreement with Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC valued at approximately $197.1 million (effective 2024-02-20).","evidence_excerpt":"On February 20, 2024, Iovance Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 23,014,000 shares of common stock (the “Shares”) (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924025617/0001104659-24-025617-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC"},{"label":"Value","value":"approximately $197.1 million"},{"label":"Effective","value":"2024-02-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}